Genscript Biotech Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genscript Biotech Corporation
Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.
The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Legend Biotech USA Inc.
- Legend Biotech Ireland Limited
- Nanjing GenScript Co Ltd
- Nanjing Legend Biotechnology Co., Ltd.
- GenScript ProBio